BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henry ML. Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. Clin Transplant. 1999;13:209-220. [PMID: 10383101 DOI: 10.1034/j.1399-0012.1999.130301.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Blume C, Hollenbeck M, Ivens K, Heering P, Hetzel G, Grabensee B. Conversion from cyclosporine to tacrolimus prevents transplant function loss due to acute steroid-resistant or chronic rejection in renal allograft recipients. Transplantation Proceedings 2001;33:3161-3. [DOI: 10.1016/s0041-1345(01)02346-6] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Lorant J, Larcher T, Jaulin N, Hedan B, Lardenois A, Leroux I, Dubreil L, Ledevin M, Goubin H, Moullec S, Deschamps JY, Thorin C, André C, Adjali O, Rouger K. Vascular Delivery of Allogeneic MuStem Cells in Dystrophic Dogs Requires Only Short-Term Immunosuppression to Avoid Host Immunity and Generate Clinical/Tissue Benefits. Cell Transplant 2018;27:1096-110. [PMID: 29871519 DOI: 10.1177/0963689718776306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
3 Veroux P, Veroux M, Puliatti C, Morale W, Cappello D, Valvo M, Macarone M. Tacrolimus-induced neurotoxicity in kidney transplant recipients. Transplantation Proceedings 2002;34:3188-90. [DOI: 10.1016/s0041-1345(02)03606-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Meaney CJ, Arabi Z, Venuto RC, Consiglio JD, Wilding GE, Tornatore KM. Validity and reliability of a novel immunosuppressive adverse effects scoring system in renal transplant recipients. BMC Nephrol 2014;15:88. [PMID: 24925208 DOI: 10.1186/1471-2369-15-88] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
5 Altaca G, Berber I, Aydın C, Titiz I. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. Transplantation Proceedings 2002;34:2079-80. [DOI: 10.1016/s0041-1345(02)02858-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Solà R, Díaz JM, Guirado L, Sainz Z, Gich I, Picazo M, García R, Abreu E, Ortiz F, Alcaraz A. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. Transplant Proc 2003;35:1699-700. [PMID: 12962763 DOI: 10.1016/s0041-1345(03)00607-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Spolidorio L, Spolidorio D, Massucato E, Neppelenbroek K, Campanha N, Sanches M. Oral health in renal transplant recipients administered cyclosporin A or tacrolimus. Oral Diseases 2006;12:309-14. [DOI: 10.1111/j.1601-0825.2005.01200.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
8 Bucuvalas JC, Ryckman FC, Arya G, Andrew B, Lesko A, Cole CR, James B, Kotagal U. A Novel Approach to Managing Variation: Outpatient Therapeutic Monitoring of Calcineurin Inhibitor Blood Levels in Liver Transplant Recipients. The Journal of Pediatrics 2005;146:744-50. [DOI: 10.1016/j.jpeds.2005.01.036] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
9 Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008;100:403-11; quiz 412-4, 468. [PMID: 18517070 DOI: 10.1016/S1081-1206(10)60462-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Chen X, Zhang Y, Yu J. Symptom Experience and Related Predictors in Liver Transplantation Recipients. Asian Nurs Res (Korean Soc Nurs Sci) 2021;15:8-14. [PMID: 33188944 DOI: 10.1016/j.anr.2020.11.001] [Reference Citation Analysis]
11 Schrem H, Lück R, Becker T, Nashan B, Klempnauer J. Update on liver transplantation using cyclosporine. Transplantation Proceedings 2004;36:2525-31. [DOI: 10.1016/j.transproceed.2004.10.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
12 Wayman M, Oniscu G, Forsythe J, Whitworth C. Two-year outcome in renal allograft recipients comparing neoral-led with tacrolimus-led therapy. Transplantation Proceedings 2002;34:1663-5. [DOI: 10.1016/s0041-1345(02)02971-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Kidokoro K, Satoh M, Nagasu H, Sakuta T, Kuwabara A, Yorimitsu D, Nishi Y, Tomita N, Sasaki T, Kashihara N. Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change. Kidney Blood Press Res 2012;35:549-57. [PMID: 22890154 DOI: 10.1159/000339494] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
14 Jiang H, Yang XF, Wynn C, Soriano R, Krishnan K, Fujimura T, Kobayashi M. IL-10: a tacrolimus-specific cytotoxic mediator in ongoing allograft rejection. Transplant Proc 2001;33:510-3. [PMID: 11266931 DOI: 10.1016/s0041-1345(00)02115-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol 2006;46:76-87. [PMID: 16397287 DOI: 10.1177/0091270005282628] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
16 Baek CH, Kim CD, Lee DR, Kim YH, Yang J, Kim BS, Lee JS, Han SY, Kim SW, Lee S, Lee KW, Kong JM, Shin BC, Lee SH, Chae DW, Kwon YJ, Jiang H, Lee H, Park SK. Randomized, Open-Label, Phase IV, Korean Study of Kidney Transplant Patients Converting From Cyclosporine to Prolonged-Release Tacrolimus Plus Standard- or Reduced-Dose Corticosteroids. Transplant Proc 2019;51:749-60. [PMID: 30979460 DOI: 10.1016/j.transproceed.2019.01.057] [Reference Citation Analysis]
17 Bucuvalas JC, Campbell KM, Cole CR, Guthery SL. Outcomes After Liver Transplantation: Keep the End in Mind. Journal of Pediatric Gastroenterology & Nutrition 2006;43:S41-8. [DOI: 10.1097/01.mpg.0000226389.64236.dc] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
18 Riva N, Guido PC, Ibañez J, Licciardone N, Rousseau M, Mato G, Monteverde M, Schaiquevich P. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. Int J Clin Pharm 2014;36:779-86. [DOI: 10.1007/s11096-014-9959-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
19 Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005;5:CD003961. [PMID: 16235347 DOI: 10.1002/14651858.cd003961.pub2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 3.9] [Reference Citation Analysis]
20 Munagala MR, Phancao A. Managing Cardiovascular Risk in the Post Solid Organ Transplant Recipient. Med Clin North Am. 2016;100:519-533. [PMID: 27095643 DOI: 10.1016/j.mcna.2016.01.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
21 Tylicki L, Habicht A, Watschinger B, Hörl WH. Treatment of hypertension in renal transplant recipients: . Current Opinion in Urology 2003;13:91-8. [DOI: 10.1097/00042307-200303000-00002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
22 Minguito-Carazo C, Gómez-Bueno M, Almenar-Bonet L, Barge-Caballero E, González-Vílchez F, Delgado-Jiménez JF, María Arizón Del Prado J, Sousa-Casasnovas I, Mirabet-Pérez S, González-Costello J, Sobrino-Márquez JM, Pérez-Villa F, Díaz-Molina B, Rábago Juan-Aracil G, Blasco-Peiró T, De la Fuente Galán L, Garrido-Bravo I, García-Guereta L, Camino M, Albert-Brotons DC, Muñiz J, Crespo-Leiro MG. Malignancy following heart transplantation: differences in incidence and prognosis between sexes - a multicenter cohort study. Transpl Int 2021;34:882-93. [PMID: 33482021 DOI: 10.1111/tri.13827] [Reference Citation Analysis]
23 Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J. A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1: . Transplantation 2005;80:457-65. [DOI: 10.1097/01.tp.0000165847.05787.08] [Cited by in Crossref: 172] [Cited by in F6Publishing: 146] [Article Influence: 10.8] [Reference Citation Analysis]
24 Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583-595. [PMID: 15023151 DOI: 10.1046/j.1600-6143.2003.00372.x] [Cited by in Crossref: 317] [Cited by in F6Publishing: 265] [Article Influence: 18.6] [Reference Citation Analysis]
25 Han SS, Kim DH, Lee SM, Han NY, Oh JM, Ha J, Kim YS. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pract 2012;31:157-62. [PMID: 26894021 DOI: 10.1016/j.krcp.2012.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
26 Duijnhoven EMV, Boots JMM, Christiaans MHL, Wolffenbuttel BHR, Hooff JPV. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12:583-8. [PMID: 11181807 DOI: 10.1681/ASN.V123583] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
27 Quirós-tejeira RE, Chang I, Bristow LJ, Karpen SJ, Goss JA. Treatment of acute tacrolimus whole-blood elevation with phenobarbital in the pediatric liver transplant recipient. Pediatric Transplantation 2005;9:792-6. [DOI: 10.1111/j.1399-3046.2005.00368.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
28 Masuda S, Goto M, Kiuchi T, Uemoto S, Kodawara T, Saito H, Tanaka K, Inui K. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl 2003;9:1108-13. [PMID: 14526408 DOI: 10.1053/jlts.2003.50179] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
29 Rely K, Galindo-Suárez RM, Alexandre PK, García-García EG, Muciño-Ortega E, Salinas-Escudero G, Martínez-Valverde S. Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico. Value Health Reg Issues 2012;1:211-7. [PMID: 29702902 DOI: 10.1016/j.vhri.2012.09.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Saland JM, Ginsberg H, Fisher EA. Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management: . Current Opinion in Pediatrics 2002;14:197-204. [DOI: 10.1097/00008480-200204000-00009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
31 Miyazaki T, Oto T, Okumura M, Date H, Shiraishi T, Okada Y, Chida M, Kondo T, Nagayasu T. De novo malignancy after lung transplantation in Japan. Gen Thorac Cardiovasc Surg 2016;64:543-8. [DOI: 10.1007/s11748-016-0672-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
32 Dall'Agnol DJ, Hauschildt AT, Lima MB, Corá LA, Teixeira MC, Américo MF. Effects of immunosuppressive drugs on gastrointestinal transit of rats: effects of tacrolimus, cyclosporine, and prednisone. Transplant Proc 2014;46:1872-4. [PMID: 25131057 DOI: 10.1016/j.transproceed.2014.05.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
33 Dasgupta A, Krasowski MD. Immunosuppressants. Therapeutic Drug Monitoring Data. Elsevier; 2020. pp. 271-307. [DOI: 10.1016/b978-0-12-815849-4.00013-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Roche E, Reig JA, Campos A, Paredes B, Isaac JR, Lim S, Calne RY, Soria B. Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. Transpl Immunol 2005;15:113-29. [PMID: 16412956 DOI: 10.1016/j.trim.2005.09.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
35 Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet 2015;54:993-1025. [DOI: 10.1007/s40262-015-0282-2] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
36 Hernández D, Alvarez A, Torres A, Oppenheimer F, Cobo M, González-Posada J, Jiménez A, Lorenzo V, Torregrosa V. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 2003;35:1727-9. [PMID: 12962773 DOI: 10.1016/s0041-1345(03)00630-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
37 Kawano T, Matsuse H, Kondo Y, Machida I, Saeki S, Tomari S, Mitsuta K, Fukushima C, Obase Y, Shimoda T, Kohno S. Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin. J Allergy Clin Immunol 2004;114:1278-81. [PMID: 15577823 DOI: 10.1016/j.jaci.2004.09.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
38 Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59:323-389. [PMID: 10730553 DOI: 10.2165/00003495-200059020-00021] [Cited by in Crossref: 189] [Cited by in F6Publishing: 146] [Article Influence: 9.0] [Reference Citation Analysis]
39 Jeon SH, Park HM, Kim SJ, Lee MY, Kim GB, Rahman MM, Woo JN, Kim IS, Kim JS, Kang HS. Taurine reduces FK506-induced generation of ROS and activation of JNK and Bax in Madin Darby canine kidney cells. Hum Exp Toxicol 2010;29:627-33. [PMID: 20056734 DOI: 10.1177/0960327109359019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
40 Martins L, Ventura A, Branco A, Carvalho M, Henriques A, Dias L, Sarmento A, Amil M. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? Transplantation Proceedings 2004;36:877-9. [DOI: 10.1016/j.transproceed.2004.03.083] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
41 Riva N, Schaiquevich P, Cáceres Guido P, Halac E, Dip M, Imventarza O. Pharmacoepidemiology of tacrolimus in pediatric liver transplantation. Pediatr Transplantation 2017;21:e12982. [DOI: 10.1111/petr.12982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mcewan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK: . PharmacoEconomics 2006;24:67-79. [DOI: 10.2165/00019053-200624010-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
43 Solà R, Guirado L, Díaz JM, Facundo C, Gich I, Chuy E, Cabezas A. Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study. Int Immunopharmacol. 2005;5:129-131. [PMID: 15589471 DOI: 10.1016/j.intimp.2004.09.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
44 Marchiori PE, Lino AM, Britto N, Bacchella T, Machado MC, Mies S, Massarollo P, Scaff M. Neuropsychiatric complications due to organ transplantation: a survey of 1499 Brazilian patients at a single center in São Paulo, Brazil. Transplantation Reviews 2005;19:115-22. [DOI: 10.1016/j.trre.2005.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Heits N, Keserovic D, Mund N, Ehmke N, Bernsmeier A, Hendricks A, Gunther R, Witt K, Becker T, Braun F. Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy. Transplant Direct 2017;3:e146. [PMID: 28405602 DOI: 10.1097/TXD.0000000000000658] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
46 Murata A, Sekiya K, Watanabe Y, Yamaguchi F, Hatano N, Izumori K, Tokuda M. A novel inhibitory effect of d-allose on production of reactive oxygen species from neutrophils. Journal of Bioscience and Bioengineering 2003;96:89-91. [DOI: 10.1016/s1389-1723(03)90104-6] [Cited by in Crossref: 84] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
47 Scheel A, Blaschke S, Schettler V, Mayer C, Müller G, Bittermann H, Grunewald R. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. Transplantation Proceedings 2001;33:3693-4. [DOI: 10.1016/s0041-1345(01)02506-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Rossi M, Mennini G, Lai Q, Ginanni Corradini S, Drudi FM, Pugliese F, Berloco PB. Liver transplantation(). J Ultrasound 2007;10:28-45. [PMID: 23396075 DOI: 10.1016/j.jus.2007.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Reisæter A, Hartmann A. Risk factors and incidence of posttransplant diabetes mellitus. Transplantation Proceedings 2001;33:S8-S18. [DOI: 10.1016/s0041-1345(01)02229-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
50 Zhang W, Egashira N, Masuda S. Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. Int J Mol Sci 2019;20:E3210. [PMID: 31261959 DOI: 10.3390/ijms20133210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
51 Venuto RC, Meaney CJ, Chang S, Leca N, Consiglio JD, Wilding GE, Brazeau D, Gundroo A, Nainani N, Morse SE, Cooper LM, Tornatore KM. Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes. Medicine (Baltimore) 2015;94:e1315. [PMID: 26376376 DOI: 10.1097/MD.0000000000001315] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
52 Fellstr??m B. Risk Factors for and Management of Post-Transplantation Cardiovascular Disease: . BioDrugs 2001;15:261-78. [DOI: 10.2165/00063030-200115040-00006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
53 Jiang H, Wynn C, Pan F, Ebbs A, Erickson LM, Kobayashi M. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production1: . Transplantation 2002;73:1808-17. [DOI: 10.1097/00007890-200206150-00019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
54 Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004;43:623-53. [PMID: 15244495 DOI: 10.2165/00003088-200443100-00001] [Cited by in Crossref: 528] [Cited by in F6Publishing: 434] [Article Influence: 31.1] [Reference Citation Analysis]
55 Joh S, Na H, Son JG, Lee AY, Ahn C, Ji D, Wi J, Jeong MS, Lee S, Lee TG. Quantitative Analysis of Immunosuppressive Drugs Using Tungsten Disulfide Nanosheet-Assisted Laser Desorption Ionization Mass Spectrometry. ACS Nano 2021;15:10141-52. [DOI: 10.1021/acsnano.1c02016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
56 Muirhead N, House A, Hollomby D, Jevnikar A. A comparison between cyclosporine and tacrolimus-based immunosuppression for renal allografts: renal function and blood pressure after 5 years. Transplantation Proceedings 2003;35:2391-4. [DOI: 10.1016/j.transproceed.2003.09.094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Takatsuki M, Chen C, de Villa V, Chen Y, Wang C, Wang S, Cheng Y, Huang T, Jawan B, Eng H. Neoral-based immunosuppression in living donor liver transplantation. Transplantation Proceedings 2001;33:3450. [DOI: 10.1016/s0041-1345(01)02487-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
58 Zhang J, Liu Z, Tao C, Lin X, Zhang M, Zeng L, Chen X, Song H. Cationic nanoemulsions with prolonged retention time as promising carriers for ophthalmic delivery of tacrolimus. Eur J Pharm Sci 2020;144:105229. [PMID: 31958581 DOI: 10.1016/j.ejps.2020.105229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
59 Greanya ED, Poulin E, Partovi N, Shapiro RJ, Al-khatib M, Ensom MHH. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. American Journal of Health-System Pharmacy 2012;69:134-42. [DOI: 10.2146/ajhp110287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
60 Brenner MJ, Fox IK, Kawamura DH, Yu VM, Lowe JB, Hunter DA, Mackinnon SE. Delayed Nerve Repair Is Associated With Diminished Neuroenhancement by FK506: . The Laryngoscope 2004;114:570-6. [DOI: 10.1097/00005537-200403000-00034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
61 Hisamura F, Kojima-yuasa A, Kennedy DO, Matsui-yuasa I. Protective Effect of Green Tea Extract and Tea Polyphenols against FK506-Induced Cytotoxicity in Renal Cells. Basic Clin Pharmacol Toxicol 2006;98:192-6. [DOI: 10.1111/j.1742-7843.2006.pto_284.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
62 Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 2015;30:2073-84. [PMID: 25801207 DOI: 10.1007/s00467-015-3075-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
63 Vigil KJ, Pasumarthy A, Johnson LB, Sheppard T, El-ghoroury M, del Busto R. Nocardiosis in Renal Transplant Patients: Role of Current Immunosuppressant Agents. Infectious Diseases in Clinical Practice 2007;15:171-3. [DOI: 10.1097/01.idc.0000269909.41735.27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
64 Ott R, Bussenius-kammerer M, Reck T, Koch CA, Kissler H, Hohenberger W, Muller V. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients. Transplant Int 2004;17:39-43. [DOI: 10.1111/j.1432-2277.2004.tb00381.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Fox IK, Mackinnon SE. Experience with nerve allograft transplantation. Semin Plast Surg 2007;21:242-9. [PMID: 20567677 DOI: 10.1055/s-2007-991194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
66 Oğütmen B, Tuğlular S, Cakalağaoğlu F, Ozener C, Akoğlu E. Transforming growth factor-beta1, vascular endothelial growth factor, and bone morphogenic protein-7 expression in tacrolimus-induced nephrotoxicity in rats. Transplant Proc 2006;38:487-9. [PMID: 16549155 DOI: 10.1016/j.transproceed.2005.12.048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
67 Zhou X, Yang G, Davis CA, Doi SQ, Hirszel P, Wingo CS, Agarwal A. Hydrogen peroxide mediates FK506-induced cytotoxicity in renal cells. Kidney International 2004;65:139-47. [DOI: 10.1111/j.1523-1755.2004.00380.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
68 Dimény EM. Cardiovascular disease after renal transplantation. Kidney Int Suppl. 2002;78-84. [PMID: 11982818 DOI: 10.1046/j.1523-1755.61.s80.14.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
69 Winkler M. Cyclosporin as Baseline Immunosuppression in Solid Organ Transplantation: . BioDrugs 2000;14:185-93. [DOI: 10.2165/00063030-200014030-00004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Orme ME, Jurewicz WA, Kumar N, Mckechnie TL. The Cost Effectiveness of Tacrolimus versus Microemulsified Cyclosporin: A 10-Year Model of Renal Transplantation Outcomes. PharmacoEconomics 2003;21:1263-76. [DOI: 10.2165/00019053-200321170-00003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
71 Kawai R, Ito S, Aida T, Hattori H, Kimura T, Furukawa T, Mori K, Sanbuissho A, Kawada T. Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats. Journal of Immunotoxicology 2012;10:40-8. [DOI: 10.3109/1547691x.2012.691122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
72 Gao W, Yang X, Lin Z, He B, Mei D, Wang D, Zhang H, Zhang H, Dai W, Wang X, Zhang Q. The use of electronic-neutral penetrating peptides cyclosporin A to deliver pro-apoptotic peptide: A possibly better choice than positively charged TAT. J Control Release 2017;261:174-86. [PMID: 28662902 DOI: 10.1016/j.jconrel.2017.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
73 Domhan S, Zeier M, Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrology Dialysis Transplantation 2008;24:1097-103. [DOI: 10.1093/ndt/gfn605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
74 Nair N, Gongora E, Mehra MR. Long-term immunosuppression and malignancy in thoracic transplantation: Where is the balance? The Journal of Heart and Lung Transplantation 2014;33:461-7. [DOI: 10.1016/j.healun.2014.03.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
75 Riva N, Dip M, Halac E, Cáceres Guido P, Woillard JB, Licciardone N, Chan D, Buendía J, Borgnia D, Bosaleh A, de Davila MT, Imventarza O, Schaiquevich P. Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation. Ther Drug Monit 2018;40:401-10. [PMID: 29621122 DOI: 10.1097/FTD.0000000000000517] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
76 Stephany BR, Alao B, Budev M, Boumitri M, Poggio ED. Hyperlipidemia Is Associated With Accelerated Chronic Kidney Disease Progression After Lung Transplantation. Am J Transplant 2007;7:2553-60. [DOI: 10.1111/j.1600-6143.2007.01968.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]